GlassScriptPhysician profile
Farzin Samadi
NPI 1336197409
$4,858.12
in general payments reported to CMS, 2019-2025
35 companies · $334 in 2025
The $334 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $384 · 2020: $436 · 2021: $796 · 2022: $1,214 · 2023: $722 · 2024: $972 · 2025: $334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,029.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,028.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $663.11 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $590.36 | 2019-2024 | Xifaxan, Trulance |
| Abbvie INC. | $510.93 | 2019-2024 | Viberzi, Linzess |
| Amgen INC. | $380.11 | 2019-2024 | Repatha |
| Daiichi Sankyo INC. | $313.79 | 2020-2025 | Injectafer |
| Novo Nordisk INC | $271.05 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Kiniksa Pharmaceuticals International, Plc | $270.34 | 2024 | Arcalyst |
| Janssen Biotech, INC. | $167.46 | 2019-2025 | Tremfya |
| Amarin Pharma, INC. | $156.92 | 2021-2023 | |
| Lilly USA, LLC | $154.29 | 2021-2024 | Mounjaro, Zepbound |
| Regeneron Healthcare Solutions, INC. | $139.86 | 2022-2025 | Dupixent |
| Genzyme Corporation | $129.69 | 2019-2024 | |
| Edwards Lifesciences Corporation | $122.90 | 2022-2025 | Sapien 3 Ultra Resilia |
| Nestle Healthcare Nutrition INC. | $96.11 | 2020-2023 | |
| Phathom Pharmaceuticals, INC. | $93.49 | 2024-2025 | Voquezna |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $90.77 | 2021-2024 | Lifevest |
| Biohaven Pharmaceutical Holding Company LTD. | $85.26 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $77.30 | 2023-2024 | Wainua, Breztri |
| Kiniksa Pharmaceuticals, LTD. | $64.65 | 2022 | |
| Merck Sharp & Dohme LLC | $63.80 | 2021-2023 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $60.12 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.52 | 2022-2024 | Jardiance |
| Cumberland Pharmaceuticals, INC. | $36.91 | 2020-2022 | |
| Pfizer INC. | $34.68 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $33.26 | 2021-2023 | Camzyos |
| Alnylam Pharmaceuticals INC. | $26.56 | 2022 | |
| Heartflow, INC. | $24.98 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $23.59 | 2024 | Iqirvo |
| Lexicon Pharmaceuticals, INC. | $20.48 | 2023 | Inpefa |
| Scpharmaceuticals INC. | $20.28 | 2023 | |
| Alfasigma USA, INC. | $19.91 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $19.18 | 2021 | |
| Millicent US INC | $18.72 | 2025 | Intrarosa, Femlyv |
| Vivus LLC | $13.99 | 2025 | Pancreaze |
| Itamar Medical INC | $13.75 | 2024 | Watchpatone |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farzin Samadi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.